GeneDx is trading 4.47% higher at $76.36, with broader-market strength a possible contributor on October 5, 2026.
- The supplied market context shows the S&P 500 up 0.64% and Nasdaq up 1.03%.
- Softer September jobs data eased concerns about further Fed tightening and supported U.S. equities.
- No clear company-specific announcement explaining the move appeared in available search results; GeneDx’s latest listed release was its October 2 Easy Order announcement.